Drug
Emricasan clinical trials
Also written IDN-6556 and PF-03491390.
- studies test it
- 17
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How studies write it
Studies that test it under each name
Name
Development codes
- IDN-6556
- 13
Studies by the year they started
17 studies that test it; most in 2014 (6)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 6 |
| 2016 | 3 |
| 2017 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 12
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 1
Conatus Pharmaceuticals Inc. (12) · Meridian Bioscience, Inc. (2) · Histogen (2) · University of Alberta (1)
Studies
Open first, then newest update. How each study uses emricasan is read from its arms, and is right about nine times in ten.
Testing it · 17
- Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14CompletedMeridian Bioscience, Inc.NCT03439189Written as Emricasan
- Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17TerminatedMeridian Bioscience, Inc.NCT03462576Written as Emricasan
- Caspase Inhibition in Islet TransplantationCompletedPhase 1/2University of AlbertaNCT01653899Written as IDN-6556
- Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal HypertensionCompletedPhase 2HistogenNCT02960204Written as Emricasan
- Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19TerminatedPhase 1HistogenNCT04803227Written as Emricasan
- A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCVCompletedPhase 2Conatus Pharmaceuticals Inc.NCT02138253Written as IDN-6556
- Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) FibrosisCompletedPhase 2Conatus Pharmaceuticals Inc.NCT02686762Written as Emricasan (5 mg)
- Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH CirrhosisStatus unknownPhase 2Conatus Pharmaceuticals Inc.NCT03205345Written as Emricasan (25 mg)
- A Study of IDN-6556 in Subjects With Liver CirrhosisCompletedPhase 2Conatus Pharmaceuticals Inc.NCT02230670Written as IDN-6556
- A Study of IDN-6556 in Cirrhotic Subjects With Portal HypertensionCompletedPhase 2Conatus Pharmaceuticals Inc.NCT02230683Written as IDN-6556
- Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid TherapyTerminatedPhase 2Conatus Pharmaceuticals Inc.NCT01912404Written as IDN-6556
- A Study of IDN-6556 in Subjects With NAFLD and Raised TransaminasesCompletedPhase 2Conatus Pharmaceuticals Inc.NCT02077374Written as IDN-6556
- Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLFTerminatedPhase 2Conatus Pharmaceuticals Inc.NCT01937130Written as IDN-6556
- PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy VolunteersCompletedPhase 1Conatus Pharmaceuticals Inc.NCT02121860Written as IDN-6556
- PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy VolunteersCompletedPhase 1Conatus Pharmaceuticals Inc.NCT02039817Written as IDN-6556
- A Caspase Inhibitor in Chronic Hepatitis C (HCV) PatientsCompletedPhase 2Conatus Pharmaceuticals Inc.NCT00088140Written as IDN-6556
- Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver TransplantationCompletedPhase 2Conatus Pharmaceuticals Inc.NCT00080236Written as IDN-6556
Codes
What other systems call emricasan · ClinicalTrials.gg INT004657
- UNII (FDA) P0GMS9N47QEMRICASANConfirmed FDA, Wikidata
- Wikidata Q27077178emricasanConfirmed FDA, Wikidata
- NCI Thesaurus C76660EmricasanOne source FDA
- DrugBank DB05408One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | P0GMS9N47Q | EMRICASAN | Confirmed FDA, Wikidata |
| Wikidata | Q27077178 | emricasan | Confirmed FDA, Wikidata |
| NCI Thesaurus | C76660 | Emricasan | One source FDA |
| DrugBank | DB05408 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.